Abstract
Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Keywords: Cytokines, macrophages, immunocompetent
Current Pharmaceutical Design
Title: Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection
Volume: 9 Issue: 1
Author(s): Lia Danelishvilli and Luiz E. Bermudez
Affiliation:
Keywords: Cytokines, macrophages, immunocompetent
Abstract: Mycobacterium avium is a human pathogen that causes infection in immunocompetent as well as immunocompromised patients. Infection is acquired both by the respiratory and gastrointestinal routes, and bacterial invasion of mucosal epithelial cells is characteristic. M. avium crosses the mucosal barrier without triggering substantial inflammatory response. Once in the intestinal submucosa or in the alveolar space M. avium infects macrophages. Intracellular bacteria block the production of cytokines involved in the host response against the infection, such as TNF-α and IL-12, and suppress antigen presentation by the macrophage. Innate response against the infection is effective to certain extent but the ability of the bacterium to remain “silent” for a period of time prevents neutrophil and NK cells from effectively controlling the establishing of the infection. CD4+ T cells as well as CD8+ T cells are activated, although only CD4+ T cells appear to be effective in inducing anti-M. avium activity in macrophages. M. avium-specific CD8+ T cells undergo apoptosis early in the infection. Therefore, the immune mechanisms of the host and bacterial strategies for survival are complex and fascinating.
Export Options
About this article
Cite this article as:
Danelishvilli Lia and Bermudez E. Luiz, Role of Type I Cytokines in Host Defense Against Mycobacterium avium Infection, Current Pharmaceutical Design 2003; 9 (1) . https://dx.doi.org/10.2174/1381612033392369
DOI https://dx.doi.org/10.2174/1381612033392369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cell Clocks and Neuronal Networks: Neuron Ticking and Synchronization in Aging and Aging-Related Neurodegenerative Disease
Current Alzheimer Research Extracellular Matrix in Atherosclerosis: Hyaluronan and Proteoglycans Insights
Current Medicinal Chemistry Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD
Current Pharmaceutical Design Subunit Protein Vaccines: Theoretical and Practical Considerations for HIV-1
Current Molecular Medicine MicroRNA-203: Tumor Suppression and Beyond
MicroRNA Editorial [Hot Topic: Tropical Neurology (Guest Editor: Terezinha C.B. Montelli)]
Central Nervous System Agents in Medicinal Chemistry Epidemiology of Major Congenital Malformations with Specific Focus on Teratogens
Current Drug Safety Oxidative Stress and Post-Stroke Depression: Possible Therapeutic Role of Polyphenols?
Current Medicinal Chemistry Clinical and Pharmacological Aspects of Inflammatory Demyelinating Diseases in Childhood: An Update
Current Neuropharmacology Small Molecule Inhibitors of Multidrug Resistance Gene (MDR1) Expression: Preclinical Evaluation and Mechanisms of Action
Current Cancer Drug Targets Animal Models For Craniofacial Reconstruction by Stem/Stromal Cells
Current Stem Cell Research & Therapy Nanocrystals of Glycyrrhetinic Acid: Comparative Efficiency of Particle Size Reduction Techniques
Drug Delivery Letters How to Manage Pouchitis in Ulcerative Colitis?
Current Drug Targets Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery
Current Topics in Medicinal Chemistry Emerging Treatment Options in Severe Asthma
Current Respiratory Medicine Reviews Characterization and Pharmacokinetic Evaluation of Gamma Sterilized Ketorolac Tromethamine Loaded Albumin Microspheres for Intramuscular Administration
Current Drug Delivery Thiazole-based Chalcone Derivatives as Potential Anti-inflammatory Agents: Biological Evaluation and Molecular Modelling
Current Topics in Medicinal Chemistry Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Lentinus edodes: A Macrofungus with Pharmacological Activities
Current Medicinal Chemistry Antibody-Based Therapies in Systemic Lupus Erythematosus
Mini-Reviews in Medicinal Chemistry